Literature DB >> 30011239

How to select the appropriate "neoadjuvant therapy" for hepatocellular carcinoma.

Ken Liu1,2,3, Geoffrey W McCaughan1,2,3.   

Abstract

Entities:  

Keywords:  Bridging; downstaging; hepatocellular carcinoma; liver transplantation; locoregional therapy; neoadjuvant therapy

Year:  2018        PMID： 30011239     DOI： 10.1080/14656566.2018.1498843

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


× No keyword cloud information.
  3 in total

1.  Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations.

Authors:  Xiao-Dong Zhu; Cheng Huang; Ying-Hao Shen; Yuan Ji; Ning-Ling Ge; Xu-Dong Qu; Lingli Chen; Wen-Kai Shi; Mei-Ling Li; Jin-Jin Zhu; Chang-Jun Tan; Zhao-You Tang; Jian Zhou; Jia Fan; Hui-Chuan Sun
Journal:  Liver Cancer       Date:  2021-03-30       Impact factor: 11.740

2.  Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment.

Authors:  Shun Kaneko; Kaoru Tsuchiya; Yutaka Yasui; Yuki Tanaka; Kento Inada; Shun Ishido; Sakura Kirino; Koji Yamashita; Yuka Hayakawa; Tsubasa Nobusawa; Hiroaki Matsumoto; Tatsuya Kakegawa; Mayu Higuchi; Kenta Takaura; Shohei Tanaka; Chiaki Maeyashiki; Nobuharu Tamaki; Yuka Takahashi; Hiroyuki Nakanishi; Takumi Irie; Shun-Ichi Ariizumi; Masayuki Kurosaki; Namiki Izumi
Journal:  JGH Open       Date:  2022-04-21

Review 3.  Neoadjuvant Therapy for Hepatocellular Carcinoma.

Authors:  Zongyi Yin; Dongying Chen; Shuang Liang; Xiaowu Li
Journal:  J Hepatocell Carcinoma       Date:  2022-08-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.